Cancer Medicine最新文献

{"title":"Nomograms for predicting recurrence of HER2-positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics","authors":"Xudong Zhang,&nbsp;Hanqing Kong,&nbsp;Xiaoxue Liu,&nbsp;Qingxiang Li,&nbsp;Xinran Fang,&nbsp;Junjia Wang,&nbsp;Zihao Qin,&nbsp;Nana Hu,&nbsp;Jiawei Tian,&nbsp;Hao Cui,&nbsp;Lei Zhang","doi":"10.1002/cam4.70146","DOIUrl":"10.1002/cam4.70146","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>This study aimed to identify ultrasound and clinicopathological characteristics related to recurrence in HER2-positive (HER2+) breast cancer, and to develop nomograms for predicting recurrence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this dual-center study, we retrospectively enrolled 570 patients with HER2+ breast cancer. The ultrasound and clinicopathological characteristics of hormone receptor (HR)−/HER2+ patients and HR+/HER2+ patients were analyzed separately according to HR status. Eighty percent of the original samples from HR−/HER2+ and HR+/HER2+ patients were extracted by bootstrap sampling as the training cohorts, while the remaining 20% were used as the external validation cohorts. Informative characteristics were screened through univariate and multivariable Cox regression in the training cohorts and used to develop nomograms for predicting recurrence. The predictive accuracy was calculated using Harrell's C-index and calibration curves.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Three informative characteristics (axillary nodal status, calcification, and Adler degree) were identified in HR−/HER2+ patients, and another three (histological grade, axillary nodal status, and echogenic halo) in HR+/HER2+ patients. Based on these, two separate nomograms were constructed to assess recurrence risk. In the training cohorts, the C-index was 0.740 (95% CI: 0.667–0.811) for HR−/HER2+ nomogram, and 0.749 (95% CI: 0.679–0.820) for HR+/HER2+ nomogram. In the validation cohorts, the C-index was 0.708 (95% CI: 0.540–0.877) for HR−/HER2+ group, and 0.705 (95% CI: 0.557–0.853) for HR+/HER2+ group. The calibration curves also indicated the excellent accuracy of the nomograms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Ultrasound performance of HER2+ breast cancers with different HR status was significantly different. Nomograms integrating ultrasound and clinicopathological characteristics exhibited favorable performance and have the potential to serve as a reliable method for predicting recurrence in heterogeneous breast cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70146","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration","authors":"Alice Sýkorová,&nbsp;František Folber,&nbsp;Kamila Polgárová,&nbsp;Heidi Móciková,&nbsp;Juraj Ďuraš,&nbsp;Kateřina Steinerová,&nbsp;Aleš Obr,&nbsp;Adriana Heindorfer,&nbsp;Miriam Ladická,&nbsp;Ľubica Lukáčová,&nbsp;Erika Čellárová,&nbsp;Ivana Plameňová,&nbsp;David Belada,&nbsp;Andrea Janíková,&nbsp;Marek Trněný,&nbsp;Tereza Jančárková,&nbsp;Vít Procházka,&nbsp;Andrej Vranovský,&nbsp;Margaréta Králiková,&nbsp;Jan Vydra,&nbsp;Lukáš Smolej,&nbsp;Ľuboš Drgoňa,&nbsp;Martin Sedmina,&nbsp;Eva Čermáková,&nbsp;Robert Pytlík","doi":"10.1002/cam4.70138","DOIUrl":"10.1002/cam4.70138","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The aim of this study was to analyse the outcomes of patients with large B-cell lymphoma (LBCL) treated with chimeric antigen receptor T-cell therapy (CAR-Tx), with a focus on outcomes after CAR T-cell failure, and to define the risk factors for rapid progression and further treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analysed 107 patients with LBCL from the Czech Republic and Slovakia who were treated in ≥3rd-line with tisagenlecleucel or axicabtagene ciloleucel between 2019 and 2022.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The overall response rate (ORR) was 60%, with a 50% complete response (CR) rate. The median progression-free survival (PFS) and overall survival (OS) were 4.3 and 26.4 months, respectively. Sixty-three patients (59%) were refractory or relapsed after CAR-Tx. Of these patients, 39 received radiotherapy or systemic therapy, with an ORR of 22% (CR 8%). The median follow-up of surviving patients in whom treatment failed was 10.6 months. Several factors predicting further treatment administration and outcomes were present even before CAR-Tx. Risk factors for not receiving further therapy after CAR-Tx failure were high lactate dehydrogenase (LDH) levels before apheresis, extranodal involvement (EN), high ferritin levels before lymphodepletion (LD) and ECOG PS &gt;1 at R/P. The median OS-2 (from R/P after CAR-Tx) was 6.7 months (6-month 57.9%) for treated patients and 0.4 months (6-month 4.2%) for untreated patients (<i>p</i> &lt; 0.001). The median PFS-2 (from R/P after CAR-Tx) was 3.2 months (6-month 28.5%) for treated patients. The risk factors for a shorter PFS-2 (<i>n</i> = 39) included: CRP &gt; limit of the normal range (LNR) before LD, albumin &lt; LNR and ECOG PS &gt; 1 at R/P. All these factors, together with LDH &gt; LNR before LD and EN involvement at R/P, predicted OS-2 for treated patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings allow better stratification of CAR-Tx candidates and stress the need for a proactive approach (earlier restaging, intervention after partial remission achievement).</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70138","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Structure-based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach”","authors":"","doi":"10.1002/cam4.70174","DOIUrl":"10.1002/cam4.70174","url":null,"abstract":"<p>Islam S, Amin MA, Rengasamy KRR, Mohiuddin AKM, Mahmud S. Structure-based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach. <i>Cancer Med</i>. 2024;13(15):e70074. doi:10.1002/cam4.70074.</p><p>A second affiliation has been added for Kannan R. R. Rengasamy and reads as follows:</p><p>³Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa.</p><p>An acknowledgment section has been added and reads as follows:</p><p>Kannan R.R. Rengasamy acknowledges the Centre for High Performance Computing (CHPC), South Africa, for providing computational resources to this research project.</p><p>We apologize for this error.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70174","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional, and national burdens of leukemia from 1990 to 2019: A systematic analysis of the global burden of disease in 2019 based on the APC model","authors":"Xiang Qu,&nbsp;Anjie Zheng,&nbsp;Jie Yang,&nbsp;Jinru Zhang,&nbsp;Hongmei Qiao,&nbsp;Fan Jiang,&nbsp;Jie Zhao,&nbsp;Chunping Wang,&nbsp;Peng Ning","doi":"10.1002/cam4.7150","DOIUrl":"10.1002/cam4.7150","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Leukemia is the tenth most common cause of cancer death worldwide and one of the most important causes of disability. To understand the current status and changing trends of the disease burden of leukemia at the global, regional, and national levels, and to provide a scientific basis for the development of leukemia prevention and treatment strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Based on open data from the Global Burden of Disease Study 2019 (GBD 2019), R software was used to calculate estimated annual percentage changes to estimate trends in the age-standardized incidence (ASIR) and the age-standardized disability-adjusted life years (DALY) rate due to leukemia and its major subtypes from 1990 to 2019.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In 2019, globally, the number of incidences and DALYs of leukemia were 643.6 × 10³ (587.0 × 10³, 699.7 × 10³) and 11,657.5 × 10³ (10529.1 × 10³, 12700.7 × 10³), respectively. The ASIR (estimated annual percentage change (EAPC) = −0.37, 95%UI −0.46 to −0.28) and the age-standardized DALY rate (EAPC = −1.72, 95%UI −1.80 to −1.65) of leukemia showed a decreasing trend from 1990 to 2019. The APC model analysis showed that the age effect of leukemia risk was a “U”-shaped distribution of relative risk (RR) with increasing age from 1990 to 2019, globally. The time effect was an increase in incidence rate with increasing years but a decrease in DALY rate with increasing years. The cohort effects of both incidence and DALY rates tended to increase and then decrease with the development of the birth cohort. In 1990 and 2019, smoking, high body-mass index, occupational exposure to benzene, and occupational exposure to formaldehyde were risk factors for DALY in leukemia, especially in areas with high SDI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>From 1990 to 2019, the disease burden of leukemia showed a decreasing trend, but it is worth noting that its overall severity is still very high. The disease burden of leukemia varies greatly from region to region, and exclusive strategies for the prevention and treatment of leukemia should be developed according to the economic and cultural development of each region.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.7150","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “KBTBD7 promotes non-small cell lung carcinoma progression by enhancing ubiquitin-dependent degradation of PTEN”","authors":"","doi":"10.1002/cam4.7462","DOIUrl":"10.1002/cam4.7462","url":null,"abstract":"<p>Zou Z, Zhang B, Li Z, Lei L, Sun G, Jiang X, Guan J, Zhang Y, Xu S, Li Q. KBTBD7 promotes non-small cell lung carcinoma progression by enhancing ubiquitin-dependent degradation of PTEN. <i>Cancer Med</i>. 2022 Dec;11(23):4544–4554.</p><p>In the Abstract section, the text “Immunohistochemical staining of 104 paired NSCLC and peritumoral normal specimens indicated that KBTBD7 was highly expressed in NSCLC tissues and positively correlated with the histological type, P-TNM stage, lymph node metastasis, and tumor size” was incorrect. It should read “Immunohistochemical staining of 102 paired NSCLC and peritumoral normal specimens indicated that KBTBD7 was highly expressed in NSCLC tissues and positively correlated with the histological type, P-TNM stage, lymph node metastasis, and tumor size.”</p><p>In the Method section, 2.1 Patients and specimens “In total, 104 paired NSCLC and peritumoral normal specimens were collected from patients with NSCLC who underwent surgery at the Department of Thoracic Surgery of the First Hospital of China Medical University from 2018 to 2020.” was incorrect. It should read “In total, 102 paired NSCLC and peritumoral normal specimens were collected from patients with NSCLC who underwent surgery at the Department of Thoracic Surgery of the First Hospital of China Medical University from 2018 to 2020.”</p><p>In the Result section, 3.1, “KBTBD7 expression in 104 paired NSCLC and adjacent non-cancerous tissues was assessed by immunohistochemical staining.” was incorrect. It should read “KBTBD7 expression in 102 paired NSCLC and adjacent noncancerous tissues was assessed by immunohistochemical staining.”</p><p>In the Result section, 3.2, “Western blot assays indicated that KBTBD7 was expressed at high levels in SK, A549, H1975, H1299, and HCC827 cell lines compared to the HBE cell line (Figure 1C).” was incorrect. It should read “Western blot assays indicated that KBTBD7 was expressed at high levels in A549, SK, H460, H292, and H1299 cell lines compared to the HBE cell line (Figure 1C).”</p><p>Table 1 was incorrect. The correct table is shown here:</p><p>We apologize for these errors.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.7462","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Comprehensive analysis of clinical prognosis and biological significance of CNIH4 in cervical cancer” Wang, J, Wang, S, Wang, J, Huang, J, Lu, H, Pan, B, Pan, H, Song, Y, Deng, Q, Jin, X, Shi, G. Comprehensive analysis of clinical prognosis and biological significance of CNIH4 in cervical cancer. Cancer Med. 2023; 12(24): 22381–22394. doi: 10.1002/cam4.6734","authors":"","doi":"10.1002/cam4.70214","DOIUrl":"10.1002/cam4.70214","url":null,"abstract":"<p>In section 2.7 on page 22383, “Tubulin (1:20000, Proteintech)” should have read “Actin (1:80000, ABclonal).” In Figure 3, Part A, on page 22388, “Tubulin” was incorrect and should have read “Actin.” Please see the corrected figure below. Although we used both Actin and Tubulin as the internal reference genes in the pre-experiment, the statistics of the data show Actin instead of Tubulin.</p><p>We apologize for these errors.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70214","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of thoracic radiotherapy on first-line treatment outcomes in ES-SCLC patients","authors":"Xiaoli Mu,&nbsp;Yixin Zhou,&nbsp;Qing Liu,&nbsp;Jiantao Wang,&nbsp;Feng Xu,&nbsp;Feng Luo,&nbsp;Ke Wang,&nbsp;Lu Li,&nbsp;Panwen Tian,&nbsp;Yalun Li,&nbsp;Jiewei Liu,&nbsp;Yan Zhang,&nbsp;Jiyan Liu,&nbsp;Yan Li","doi":"10.1002/cam4.70175","DOIUrl":"10.1002/cam4.70175","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The therapeutic advantage of thoracic radiotherapy (tRT) as an adjunct to first-line immunotherapy and chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) remains unclear. We sought to elucidate this in a retrospective cohort study comparing the effectiveness and safety of tRT in combination with first-line immunotherapy and chemotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Our retrospective study included patients with ES-SCLC, treated at the West China Hospital between January 2019 and December 2022. They received first-line immunotherapy and chemotherapy and were categorized into two cohorts based on the administration of tRT. The primary outcomes were overall survival (OS) and progression-free survival (PFS). Cox regression analysis was utilized to identify potential independent predictors of prognosis and to compare the treatment outcomes across various patient subgroups. Treatment-related toxicities across both cohorts were compared using the Chi-squared test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 99patients were eligible for the study, out of which 55 received tRT. The medianduration of follow-up was 39 months. Remarkably, patients who received tRTdemonstrated superior OS and PFS in comparison to those who did not (<i>P</i> &lt; 0.05). Subgroup analysis further confirmed these findings. Multivariate analysisidentified treatment group and liver metastasis as independent prognosticfactors (<i>P</i> &lt; 0.05). The incidence of grade 3-4 adverse events showed nostatistically significant difference between the two cohorts.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Thus, weconfirmed that the addition of tRT to the conventional regimen of first-linechemotherapy and immunotherapy yields better survival outcomes without asignificant increase in toxicity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70175","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia","authors":"Xiaoxia Wu,&nbsp;Shenqi Lu,&nbsp;Xinhui Zhang,&nbsp;Zhen Yang,&nbsp;Aining Sun,&nbsp;Depei Wu,&nbsp;Huifen Zhou,&nbsp;Miao Miao","doi":"10.1002/cam4.70161","DOIUrl":"10.1002/cam4.70161","url":null,"abstract":"<p>Tyrosine kinase inhibitors (TKIs) have revolutionized Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treatment. The combination of blinatumomab and a TKI in the frontline setting has shown the safety and efficacy of the chemotherapy-free treatment approach in patients with Ph + ALL. This retrospective analysis included 19 patients with Ph + ALL and Ph-like ALL treated with the combination of blinatumomab and a TKI. Of the 14 newly diagnosed patients, the overall response, complete remission (CR), and molecular response (CMR) rates after one cycle of blinatumomab were 100% (10/10), 90% (9/10), and 57% (8/14), respectively. Of the five relapsed patients, the CR and CMR rates were 50% (2/4) and 40% (2/5). Blinatumomab in combination with TKIs is safe and effective and hence this combination therapy could be a viable therapeutic option in front-line treatment of patients with Ph + ALL.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70161","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender and melanoma subtype-based prognostic implications of MUC16 and TTN co-occurrent mutations in melanoma: A retrospective multi-study analysis","authors":"Nilesh Kodali,&nbsp;Simona Alomary,&nbsp;Abhijit Bhattaru,&nbsp;Ahmed Eldaboush,&nbsp;Robert A. Schwartz,&nbsp;Shari R. Lipner","doi":"10.1002/cam4.70199","DOIUrl":"10.1002/cam4.70199","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Most primary cutaneous melanomas have pathogenesis driven by ultraviolet exposure and genetic mutations, whereas acral lentiginous melanoma (ALM) and metastatic melanoma are much less, if at all, linked with the former. Thus, we evaluated both ultraviolet related and non-ultraviolet related melanomas. Mutations in the <i>MUC16</i> and <i>TTN</i> genes commonly occur concurrently in these melanoma patients, but their combined prognostic significance stratified by gender and cancer subtype remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The cBioPortal database was queried for melanoma studies and returned 16 independent studies. Data from 2447 melanoma patients were utilized including those with ALM, cutaneous melanoma (CM), and melanoma of unknown primary (MUP). Patients were grouped based on the presence or absence of <i>MUC16</i> and <i>TTN</i> mutations. Univariate Cox regression and Student's <i>t</i>-tests were used to analyze hazard ratios and total mutation count comparisons, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p><i>TTN</i> mutations, either alone or concurrently with <i>MUC16</i> mutations, significantly correlated with worse prognosis overall, in both genders, and in CM patients. ALM patients with both mutations had better prognoses than CM patients, while ALM patients with neither mutation had worse prognosis than CM patients. For MUP patients, only <i>MUC16</i> mutations correlated with worse prognosis. ALM patients with neither <i>MUC16</i> nor <i>TTN</i> mutations had significantly more total mutations than MUP patients, followed by CM patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p><i>TTN</i> mutations are a potential marker of poor prognosis in melanoma, which is amplified in the presence of concurrent <i>MUC16</i> mutations. ALM patients with neither gene mutations had worse prognosis, suggesting a protective effect of having both <i>MUC16</i> and <i>TTN</i> mutations. Only <i>MUC16</i> mutations conferred a worse prognosis for MUP patients. Comprehensive genetic profiling in melanoma patients may facilitate personalized treatment strategies to optimize patient outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70199","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Which social determinants of health have the highest impact in community oncology to advance patient care equity and improve health outcomes? A scoping review","authors":"Kayleigh R. Majercak,&nbsp;Emily F. Gorman,&nbsp;Nicholas J. Robert,&nbsp;Barbara Palmer,&nbsp;Henry Asante Antwi,&nbsp;C. Daniel Mullins","doi":"10.1002/cam4.70160","DOIUrl":"10.1002/cam4.70160","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>To better understand the SDOH-health equity landscape within a community oncology setting to answer the research question, “Which SDOH can have the highest impact in community oncology to advance patient care equity and improve health outcomes?”</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Arksey and O'Malley's scoping review framework was used to identify evidence related to SDOH and health equity in community oncology. The study was guided by the “10-Step Framework for Continuous Patient Engagement” and a Community Advisory Board to assure relevance to patients and community providers. Literature was retrieved from literary databases and oncology organizations' websites. Eligible studies included discussion of SDOH and health equity as outlined by the World Health Organization and Centers for Disease Control and Prevention, respectively, and involved community oncology/cancer care in outpatient settings. Studies were excluded if the SDOH-health equity relationship was not discussed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The review resulted in 61 exploratory and 17 confirmatory “intervention” studies addressing the impact of SDOH on health equity in community oncology settings. The most frequently SDOH-health equity pairs identified were the SDOH categories, <i>social inclusion and non-discrimination</i>, <i>income and social protection,</i> and <i>structural conflict,</i> all paired with the health equity category, <i>access to care/treatment</i>. Confirmatory studies focused on <i>income and social protection</i> (SDOH) and <i>access to care/treatment</i> (health equity); the SDOH categories, <i>social inclusion and non-discrimination</i> and <i>health/general literacy–patient,</i> paired with the health equity category, and <i>adherence/compliance</i>.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Literature highlights the SDOH and health equity relationship within the realm of oncology. Most studies on SDOH/health inequities in the community oncology setting are exploratory. There is the need to shift from documentation of cancer inequities to implementing solutions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70160","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}